Initiatives to make food and regenerative medicine future pillars of the business
First written in FY2016. 9 of 13 entries say "Advanced", first in FY2017. Latest entry: FY2027-H1.
1 other company's latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「By connecting our knowledge in pharmaceuticals, skincare, food products and regenerative medicine, and building on the cell science cultivated since our founding, we aim to help create a society in which people can live longer, healthier and more youthful lives, and we are working toward this goal every day.」
The company reaffirmed its direction of connecting expertise across multiple areas, including food and regenerative medicine, to develop a future health-care business based on cell science. - 2026-07-09AdvancedM&A and Subsidiary Changes
「More sophisticated marketing measures based on local market needs, faster product rollouts and integrated management of the brand strategy.」
The Company has presented more sophisticated marketing measures based on local market needs, faster product rollouts and integrated management of the brand strategy as specific initiatives. - FY2026AdvancedAnnual report
「“Develop the food business, based on evidence and trust, into our third core business.”」
The company continues to develop food as its third pillar, pursuing new product development at Eu Yan Sang International Ltd., functional enhancements for Rohto V5 and exploration in the phytoscience field. In regenerative medicine, it began a Phase II clinical trial of ADR-002K. - 2026-05-13RestatedRevision to earnings forecast
「In Japan, revenue increased as a result of product proposals tailored to customer needs and increased inbound demand.」
The Company has reaffirmed its policy of turning product proposals that address customer needs into revenue growth. - FY2026-H1AdvancedAnnual report
「Revenue increased because the results of Eu Yan Sang International Ltd., a Singapore-based manufacturer and marketer of traditional Chinese medicines and other products, and Mono Co., Ltd., an Austrian manufacturer and marketer of medicines and medical devices, were included in consolidated profit or loss from the consolidated accounting period through the third quarter of the previous fiscal year.」
The expansion of the health-care business, including food products and traditional Chinese medicines, progressed with the consolidation of Eu Yan Sang International Ltd., whose results contributed to higher revenue. - FY2025-H1AdvancedAnnual report
「Further strengthening OTC medicines and food products is essential, and Asia, which accounts for approximately 30% of sales by region, is expected to achieve further growth. By combining Eu Yan Sang International Ltd.'s strong products and brands in Asia with the company's research, technology development and sales capabilities, the company aims to create an innovative business and realize an unprecedented health-care business.」
The company has specified its strategy for strengthening food products and OTC medicines, including the acquisition of Eu Yan Sang International Ltd., which handles traditional Chinese medicines and food products, and combining its brand strength with the company's research and development and sales capabilities. - FY2024AdvancedAnnual report
「Food is an area whose importance is growing as it supports daily health maintenance and disease prevention. We will target unmet needs in this area and develop products with high levels of safety and originality.」
The company reaffirmed its policy of developing food as its third pillar and identified priority areas for functional foods. In regenerative medicine, Rohto Cell Factory Tokyo was added to the group in 2023, and the company is working to establish a stable supply system for cell therapies. - FY2022-Q1AdvancedAnnual report
「From the first quarter of the current consolidated accounting period, カフェ・カンパニー㈱, in which the Company newly acquired shares, has been included in the scope of application of the equity method.」
The report describes concrete steps in pursuing new areas, including food, namely the acquisition of shares in Cafe Company Co., Ltd. and its application of the equity method. - FY2021AdvancedAnnual report
「In March 2021, the company established a subsidiary to promote regenerative medicine approaches in orthopedics and is also developing medicines for osteoarthritis of the knee, which affects a large number of patients.」
The initiative to make regenerative medicine a future pillar of the business includes the establishment of an orthopedic subsidiary, development of a medicine for osteoarthritis of the knee and progress in clinical trials for a treatment for severe pneumonia caused by COVID-19. - FY2020RaisedAnnual report
「We will develop the food business, based on evidence and trust, into our third core business.」
The company has clearly positioned functional food as its “third pillar,” moving beyond its previous policy of making food and regenerative medicine future pillars of the business. In regenerative medicine, it also plans to commercialize life-science technologies such as adipose-derived stem cells. - FY2019-Q2AdvancedAnnual report
「In September, the company entered into a license agreement with Shionogi & Co.,Ltd. covering the development and marketing of a regenerative medicine product candidate it is developing for liver cirrhosis, which also contributed to higher revenue.」
The company made tangible progress on its regenerative medicine product candidate by entering into a development and marketing license agreement with Shionogi & Co.,Ltd. in September. - FY2017AdvancedAnnual report
「In November 2016, the company obtained a manufacturing license for specified cellular products at the Rohto Stem Cell Processing Center within the Rohto Research Village Kyoto.」
The regenerative medicine initiative has achieved tangible progress, with the stem cell processing center obtaining a manufacturing license for specified cellular products. - FY2016First statedAnnual report
「As activities expanding beyond our traditional health and beauty fields, we are actively pursuing business development in food, the foundation of good health, as well as new medical businesses such as regenerative medicine. While advancing these initiatives to establish future core businesses, we will also seek to create new synergies by linking them together.」
The company aims to make new areas such as food and regenerative medicine future pillars of its business and create synergies by connecting them with its existing businesses.